Glenmark Pharma Q4 Results: Reports Loss On One-Off Expense; Revenue In Line With Estimates
Glenmark Pharmaceuticals Ltd.'s reported an after-tax loss in the fourth quarter of fiscal 2023, though its revenue and margin were in line with estimates.
The Mumbai-based bulk and generic drugmaker's reported a net loss of Rs 428 crore in the quarter ended March as against a net profit of Rs 156 crore last year. That compares with the Rs 276 crore consensus estimate of analysts tracked by Bloomberg.
It faced a litigation settlement related to the generic cholesterol drug Zetia in the U.S., which led to the exceptional loss.
Glenmark Pharma Q4 Highlights (YoY)
Revenue rose 12% to Rs 3,374 crore, as against an estimate of Rs 3,331 crore.
Ebitda rose 31% to Rs 605 crore, as compared with a forecast of Rs 604 crore.
Margin stood at 17.9% against 15.3%. Analysts had projected it at 18.1%.
The board has recommended a dividend of Rs 2.50 per share.
"We delivered yet another year of robust performance, despite the challenging global macroeconomic environment," Glenn Saldanha, chairperson and managing director at Glenmark Pharmaceuticals, said in the exchange filing.
The company continued to make headway in launching Ryaltris, their first global branded specialty product, he said. Additionally, it initiated the Proof-of-Concept studies for four of their clinical oncology assets, which are part of the Glenmark/Ichnos pipeline.
"We look forward to continue this momentum in the coming year with double-digit revenue growth and significant improvement in Ebitda margin," Saldanha said.
Other Highlights (YoY)
India registered a decline in growth of around 6% in sales at Rs 828 crore.
"This decline was mainly on account of the impact of the divestment of few non-core brands, some impact of the National List of Essential Medicines price revisions, as well as returns of Covid-related products, the company said in the filing.
U.S. formulation business rose 15% to Rs 851 crore.
Revenue from Europe grew by 22%, while rest-of-the-world revenue rose 25%.
Shares of Glenmark Pharma closed 3.5% higher ahead of the results announcement on Friday, as compared with a 0.48% rise in the benchmark Sensex.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
